Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy

He, Yuan; Liang, Yingmin; Han, Run; Lü, Wan-Liang; Mak, Jcw; Zheng, Ying

doi:10.1016/j.jconrel.2019.10.035

Cited by 54 publications

(25 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nanocomposite formation of biodegradable copolymer PLGA and polysaccharide chitosan was reported to enhance the bronchial mucus and lung tissue adhesion and effectively deliver an anti-parathyroid agent ( Yamamoto et al, 2005 ). In case of polyethylene glycol (PEG) coating on nanocarrier (PEGylation), the mucus penetrating ability increases rather than adhesion by avoiding interaction with mucin fibers ( He et al, 2019 ). Furthermore, the presence of PEG is reported to increase the residence time of nanoparticles and reduce the cytokine based inflammations ( Patil et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19

Jermy

Ravinayagam²,

Almohazey³

et al. 2022

Applied Clay Science

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19

Jermy

Ravinayagam²,

Almohazey³

et al. 2022

Applied Clay Science

View full text Add to dashboard Cite

“…The proximal conducting airways are constituted with pseudostratified columnar epithelium composed of ciliated cells, goblet or mucus secreting cells and basal or progenitor cells. The lower to the more distal airways are progressively replaced with a simple cuboidal cell layer and there is a very thin epithelial lining in the alveoli 5 . The fate of the inhaled medicines is highly dependent on the site where they are deposited in the lungs.…”

Section: Factors Influencing the Pulmonary Exposure Of The Inhaled Medicinesmentioning

confidence: 99%

“…Generally, an inhaler device is indispensable to facilitate the deposition of inhaled medicine at the targeted sites of the lungs 5 . The inhalation devices current in use are nebulizers, metered dose inhalers (MDIs) and dry powder inhalers (DPIs) 6 .…”

Section: Introductionmentioning

confidence: 99%

Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

Guo

Bera

Shi

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.

show abstract

“…Despite numerous advantages afforded by pulmonary administration, successful aerosol delivery of biopharmaceuticals including CRISPR/Cas9-based therapeutics remains highly challenging. There exist several major anatomical and physiological barriers that prevent the successful delivery genome editing via inhalation to the lungs [19,28]. Firstly, oropharyngeal deposition of orally inhaled aerosol particles must be avoided to maximise lung deposition.…”

Section: Pathophysiological Factors Influencing Aerosol Delivery Of Genes In the Lungsmentioning

confidence: 99%

Inhalation delivery technology for genome-editing of respiratory diseases

Chow

Chang

Chan

2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

The clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/ Cas9) system has significant therapeutic potentials for lung congenital diseases such as cystic fibrosis, as well as other pulmonary disorders like lung cancer and obstructive diseases. Local administration of CRISPR/Cas9 therapeutics through inhalation can achieve high drug concentration and minimise systemic exposure. While the field is advancing with better understanding on the biological functions achieved by CRISPR/Cas9 systems, the lack of progress in inhalation formulation and delivery of the molecule may impede their clinical translation efficiently. This forward-looking review discussed the current status of formulations and delivery for inhalation of relevant biologics such as genes (plasmids and mRNAs) and proteins, emphasising on their design strategies and preparation methods. By adapting and optimising formulation strategies used for genes and proteins, we envisage that development of inhalable CRISPR/Cas9 liquid or powder formulations for inhalation administration can potentially be fast-tracked in near future.

show abstract

Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy

Cited by 54 publications

References 121 publications

PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19

PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19

Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

Inhalation delivery technology for genome-editing of respiratory diseases

Contact Info

Product

Resources

About